LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Discovery Science highlights from the 17th International Conference on Malignant Lymphoma.

    Forestieri, Gabriela / de Almeida, Joyce Marques / Napoli, Sara / Piffaretti, Deborah / Tarantelli, Chiara / Zhang, Fangwen / Mensah, Afua Adjeiwaa

    Hematological oncology

    2024  Volume 42, Issue 3, Page(s) e3275

    MeSH term(s) Humans ; Lymphoma/therapy ; Lymphoma/diagnosis ; Congresses as Topic
    Language English
    Publishing date 2024-04-19
    Publishing country England
    Document type Congress ; Journal Article
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.3275
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1816: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Processing directional information in stimuli inhibits the spatial association of luminance levels.

    Wang, Qiangqiang / Wu, Yanwen / Zhang, Fangwen / Tao, Weidong / Wang, Chao

    Attention, perception & psychophysics

    2022  Volume 84, Issue 8, Page(s) 2596–2606

    Abstract: Previous studies have found that the spatial-numerical association of the response codes (SNARC) effect automatically occurred when processing both numbers and non-symbolic magnitudes. However, this conclusion was challenged by several recent studies ... ...

    Abstract Previous studies have found that the spatial-numerical association of the response codes (SNARC) effect automatically occurred when processing both numbers and non-symbolic magnitudes. However, this conclusion was challenged by several recent studies that found no SNARC effect when processing non-symbolic magnitudes with a directional cue. In the present study, we hypothesized that automatic spatial association of non-symbolic magnitudes would be inhibited by directional cues; thus, we utilized left and right arrow stimuli with different luminance levels to systematically investigate the spatial association of luminance. To ensure that participants could effectively discriminate the luminance stimuli, we first replicated the SNARC effect in Experiment 1, by presenting rectangles with different luminance levels. Then, arrows with the same luminance levels as the rectangles were randomly presented to participants on the centre of a screen; participants completed direction classification (Experiment 2), colour classification (Experiment 3), or luminance classification (Experiment 4) tasks with these arrow stimuli. We found that (1) the SNARC effect was present when processing rectangles with different luminance levels (Experiment 1); however, (2) the Simon-like effect rather than the spatial association of luminance was observed when processing arrows with different luminance levels in the luminance-irrelevant classification tasks (Experiments 2 and 3) and the luminance-relevant classification task (Experiment 4). These results indicate that processing of a directional cue inhibited the spatial association of luminance in both luminance-relevant and luminance-irrelevant classification tasks.
    MeSH term(s) Humans ; Space Perception/physiology ; Cues ; Reaction Time/physiology
    Language English
    Publishing date 2022-10-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2464550-3
    ISSN 1943-393X ; 1943-3921
    ISSN (online) 1943-393X
    ISSN 1943-3921
    DOI 10.3758/s13414-022-02572-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2176: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.

    Li, Ling / Kong, Fei / Zhang, Lei / Li, Xin / Fu, Xiaorui / Wang, Xinhua / Wu, Jingjing / Zhang, Fangwen / Ren, Liangliang / Zhang, Mingzhi

    Investigational new drugs

    2020  Volume 38, Issue 6, Page(s) 1847–1853

    Abstract: Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma ... ...

    Abstract Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We investigated the efficacy and safety of apatinib for relapsed and refractory nasopharyngeal carcinoma in an open-label, single-arm, phase II clinical trial. Fifty-one patients with relapsed and refractory nasopharyngeal carcinoma in the First Affiliated Hospital, Zhengzhou University, who met the inclusion criteria were enrolled in the study. All patients received apatinib at an initial dose of 500 mg daily (1 cycle = 28 days). The primary and secondary endpoints were overall response rate, progression-free survival, and overall survival. We evaluated treatment effects and recorded apatinib-related adverse events by performing regular follow-ups and workup. The overall response rate (complete and partial responses) was 31.37% (16/51). The median overall survival and progression-free survival were 16 (95% CI, 9.32-22.68) and 9 months (95% CI, 5.24-12.76), respectively. Most patients tolerated treatment-related adverse events of grades 1 and 2; hypertension (29, 56.86%), proteinuria (25, 49.02%), and hand-foot syndrome (27, 52.94%) were the most common adverse events. There were no treatment-related deaths. Apatinib showed good efficacy and safety in patients with relapsed and refractory NPC.
    MeSH term(s) Adolescent ; Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Drug Resistance, Neoplasm ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Nasopharyngeal Carcinoma/drug therapy ; Nasopharyngeal Neoplasms/drug therapy ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Pyridines/adverse effects ; Pyridines/therapeutic use ; Recurrence ; Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors ; Young Adult
    Chemical Substances Antineoplastic Agents ; Protein Kinase Inhibitors ; Pyridines ; apatinib (5S371K6132) ; Vascular Endothelial Growth Factor Receptor-2 (EC 2.7.10.1)
    Language English
    Publishing date 2020-05-03
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604895-x
    ISSN 1573-0646 ; 0167-6997
    ISSN (online) 1573-0646
    ISSN 0167-6997
    DOI 10.1007/s10637-020-00925-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1823: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.

    Napoli, Sara / Cascione, Luciano / Rinaldi, Andrea / Spriano, Filippo / Guidetti, Francesca / Zhang, Fangwen / Cacciapuoti, Maria Teresa / Mensah, Afua Adjeiwaa / Sartori, Giulio / Munz, Nicolas / Forcato, Mattia / Bicciato, Silvio / Chiappella, Annalisa / Ghione, Paola / Elemento, Olivier / Cerchietti, Leandro / Inghirami, Giorgio / Bertoni, Francesco

    Haematologica

    2022  Volume 107, Issue 5, Page(s) 1131–1143

    Abstract: Enhancers are regulatory regions of DNA, which play a key role in cell-type specific differentiation and development. Most active enhancers are transcribed into enhancer RNA (eRNA) that can regulate transcription of target genes by means of in cis as ... ...

    Abstract Enhancers are regulatory regions of DNA, which play a key role in cell-type specific differentiation and development. Most active enhancers are transcribed into enhancer RNA (eRNA) that can regulate transcription of target genes by means of in cis as well as in trans action. eRNA stabilize contacts between distal genomic regions and mediate the interaction of DNA with master transcription factors. Here, we characterized an enhancer eRNA, GECPAR (germinal center proliferative adapter RNA), which is specifically transcribed in normal and neoplastic germinal center B cells from the super-enhancer of POU2AF1, a key regulatory gene of the germinal center reaction. Using diffuse large B-cell lymphoma cell line models, we demonstrated the tumor suppressor activity of GECPAR, which is mediated via its transcriptional regulation of proliferation and differentiation genes, particularly MYC and the Wnt pathway.
    MeSH term(s) Enhancer Elements, Genetic ; Humans ; Lymphoma, Large B-Cell, Diffuse/genetics ; RNA/genetics ; RNA, Untranslated ; Transcription, Genetic
    Chemical Substances RNA, Untranslated ; RNA (63231-63-0)
    Language English
    Publishing date 2022-05-01
    Publishing country Italy
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2020.267096
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.76: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens.

    Zhang, Fangwen / Li, Ling / Zhang, Lei / Li, Xin / Fu, Xiaorui / Wang, Xinhua / Wu, Jingjing / Sun, Zhenchang / Kong, Fei / Ren, Liangliang / Zhang, Mingzhi

    Blood and lymphatic cancer : targets and therapy

    2019  Volume 9, Page(s) 33–43

    Abstract: Objectives: To compare the efficacy of rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH-R) with traditional rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimens in ... ...

    Abstract Objectives: To compare the efficacy of rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH-R) with traditional rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimens in CD5+ double-hit lymphoma (DHL) and to evaluate prognostic factors.
    Methods: We retrospectively studied 139 patients with newly diagnosed DHL/THL diffuse large B-cell lymphoma (including 20 cases CD5+ and 119 cases CD5-), 87 cases were MYC/BCL2 DHL, 30 cases were MYC/BCL6 DHL, 22 cases were THL. MYC, BCL2 and BCL6 rearrangements were examined by fluorescence in-situ hybridization. CD5 is detected by immunohistochemistry (IHC).
    Results: The objective response rate (ORR) difference between CD5+ and CD5- was significant (80.0% vs 63.8%,
    Conclusion: Our retrospective study shows that CD5+ has a poorer prognosis than CD5- patients. Based on its improved lifetime and good tolerance on CD5+ patients, which is expected to become the first-line treatment for high-risk DLBCL types based on more clinical research.
    Language English
    Publishing date 2019-08-19
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2673412-6
    ISSN 1179-9889 ; 1179-9889
    ISSN (online) 1179-9889
    ISSN 1179-9889
    DOI 10.2147/BLCTT.S216292
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top